(ZVRA) Zevra Therapeutics, Inc. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ZVRA) Zevra Therapeutics, Inc. Complete Analysis Pack
Your Credibility Toolkit Starts Here
This Zevra Therapeutics, Inc. SWOT Analysis summarizes what the company does, how its products are used, and presents a structured look at strengths, weaknesses, opportunities, and threats; the page already includes a real preview/sample so you can judge style and substance before buying. Purchase the full version to receive the complete, ready-to-use SWOT report for research, strategy, or investment decisions.
Strengths
2 FDA-approved products
Zevra Therapeutics, Inc. has 2 FDA-approved products, AZSTARYS and APADAZ, which gives it commercial-stage proof, not just pipeline hope. That lowers dependence on a single clinical asset and shows the Company can move programs through FDA review and into the market. In FY2025, this approval base supports a more durable revenue mix and a clearer path to scale.
Proprietary LAT platform
Zevra Therapeutics’ Ligand Activated Therapy platform turns known compounds into prodrugs, giving it a clear edge in drug design and lifecycle management. That lets the Company create new formulations and pursue new indications from one chemistry base, which can lower development risk versus starting from scratch.
This matters after MIPLYFFA, the Company’s FDA-approved NPC therapy, because LAT can extend value beyond a single launch. It also gives Zevra Therapeutics a repeatable way to build assets with better dosing or delivery traits.
Rare-disease and CNS focus
Zevra Therapeutics, Inc. focuses on high-unmet-need CNS niches like idiopathic hypersomnia, narcolepsy, stimulant use disorder, and ADHD, which helps it build a sharper clinical and commercial position. These are small, specialized markets, but treatment options are still limited, so even modest uptake can matter. The company also had one FDA-approved product in 2025, which supports execution in targeted patient groups.
Phase II pipeline momentum
Zevra Therapeutics has 2 Phase II assets, KP1077 for idiopathic hypersomnia and narcolepsy, and KP879 for stimulant use disorder. That mid-stage breadth gives the Company more than one shot at value creation, since positive Phase II data can support higher partnering, licensing, or valuation upside.
For a small biotech, multiple programs in the same stage can also spread clinical risk across different rare and underserved markets.
- 2 Phase II programs
- KP1077: idiopathic hypersomnia, narcolepsy
- KP879: stimulant use disorder
- More shots at value creation
Partnership and licensing base
Zevra Therapeutics, Inc. has partnership and licensing ties with KVK-Tech, Inc. and Commave Therapeutics SA, which can widen development, manufacturing, and commercial reach without Zevra funding all steps itself. These deals also signal outside validation of Zevra Therapeutics, Inc. assets, since partners only commit when they see usable value. In biotech, that kind of third-party backing can matter as much as cash.
- وسع reach through partners
- Lower internal capital load
- Signals asset validation
Zevra Enters FY2025 With 3 Approved Therapies and 2 Phase II Shots
Zevra Therapeutics, Inc. has 2 FDA-approved products, AZSTARYS and APADAZ, plus MIPLYFFA, so it enters FY2025 with 3 approved therapies and lower single-asset risk.
Its Ligand Activated Therapy platform and 2 Phase II programs, KP1077 and KP879, give the Company repeatable shots at value creation in rare CNS markets.
| FY2025 Strength | Data |
|---|---|
| FDA-approved products | 3 |
| Phase II assets | 2 |
| Core edge | LAT platform |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Zevra Therapeutics, Inc.’s business strategy
Editable Excel File
Provides a quick SWOT snapshot for Zevra Therapeutics, Inc. to reduce strategic guesswork and speed decisions.
Reference Sources
Provides a concise bibliography linking each key Zevra Therapeutics claim to primary industry reports, patents, clinical trial registries, and regulatory data for fast, defensible due diligence.
Weaknesses
Limited marketed portfolio
Zevra Therapeutics, Inc. has only 2 FDA-approved products, so revenue is still tied to a very small base. That makes execution on each launch, refill rate, and payer access critical, because one weak product can quickly hit total sales.
Heavy reliance on clinical-stage assets
Zevra Therapeutics still leans on clinical-stage assets, with key pipeline programs in Phase II as of 2025, so future growth depends on trial success, safety, and FDA review. That keeps late-stage development risk high, because one failed readout can delay revenue by years. Even with its current commercial base, the company still needs clinical wins to expand.
Narrow therapeutic concentration
Zevra Therapeutics is still concentrated in a few rare CNS and stimulant-linked programs, including its Niemann-Pick type C and urea-cycle disorder assets. That tight focus limits diversification, so one trial miss, label issue, or payer setback can hit more than one revenue stream. With only a small number of shots on goal, pipeline risk stays high.
U.S.-centric business scope
Zevra Therapeutics, Inc. still leans mainly on the U.S. for sales, so it misses out on ex-U.S. demand and currency diversification. That narrow scope also makes results more exposed to U.S. payer pressure, FDA timing, and coverage shifts, which can hit pricing and access fast.
- U.S.-only focus limits global upside
- Higher exposure to payer cuts
- More tied to FDA and CMS decisions
History of rebranding and transition
Zevra Therapeutics, Inc. was formerly KemPharm, Inc. and rebranded in February 2023, so the company is still paying the cost of a reset in market recognition. That kind of transition can force extra spending on brand education and slow trust-building with doctors, payers, and investors. It also signals that the business model is still proving whether its FY2025 growth can hold up after the name change.
Former name: KemPharm, Inc.
Rebrand completed: February 2023
Higher brand-building and education needs
Post-transition growth still needs proof
Zevra’s Small Base and Phase II Pipeline Keep Risk High
Zevra Therapeutics, Inc. has just 2 FDA-approved products, so FY2025 revenue is still tied to a very small base. Its pipeline still leans on Phase II assets, which keeps clinical and FDA risk high. Sales are still mostly U.S.-based, so payer pressure and coverage shifts can hit fast.
| Weakness | Data |
|---|---|
| Approved products | 2 |
| Late-stage pipeline | Phase II |
| Geographic mix | U.S.-heavy |
What You See Is What You Get
Zevra Therapeutics, Inc. Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is drawn directly from the full Zevra Therapeutics, Inc. report and highlights key strengths, weaknesses, opportunities, and threats to inform investment and strategic decisions.
Opportunities
Phase II upside for KP1077
Phase II data for KP1077 could open a new revenue stream for Zevra Therapeutics, Inc. in idiopathic hypersomnia and narcolepsy, two sleep disorders with few approved options and strong unmet need. If results are positive, the program could broaden Zevra Therapeutics, Inc.'s CNS reach and help de-risk its LAT platform in another indication. That matters because one win can lift both pipeline value and partnering appeal.
Phase II upside for KP879
KP879’s Phase II advance in stimulant use disorder could target a large unmet need: the 2024 National Survey on Drug Use and Health estimated 4.2 million people had stimulant misuse in the U.S. alone, and there are still no FDA-approved medicines for cocaine or methamphetamine use disorder.
If Zevra Therapeutics, Inc. shows a clear efficacy signal, KP879 could stand out in a market with few direct treatment options and high relapse risk. That kind of readout could support a differentiated franchise and new value beyond the current rare-disease base.
Expand AZSTARYS adoption
AZSTARYS is approved for ADHD in patients 6 years and older, giving Zevra a foothold in a U.S. market where about 7 million children 3-17 have ADHD. Broader prescribing, better payer coverage, and more physician familiarity can lift use. That matters because one approved brand can become a long-term commercial platform in a large, repeat-use market.
Broaden APADAZ utilization
APADAZ is an immediate-release benzhydrocodone and acetaminophen tablet, and Zevra Therapeutics, Inc. can still widen awareness in short-term pain settings where clinicians want an oral option with clear dosing. If Zevra lifts prescribing in even a narrow slice of the acute-pain market, APADAZ can add a second revenue stream and reduce reliance on a small set of rare-disease assets. The product’s 12 mg/325 mg strength gives it a clear, simple positioning.
- Expand use in acute-pain care
- Target better prescriber awareness
- Add portfolio diversification
Leverage rare-disease positioning
Zevra Therapeutics can use rare-disease focus to target small patient groups with high unmet need, where premium pricing is more common. The rare-disease market serves about 300 million people worldwide across more than 7,000 diseases, so expertise in orphan-drug trials and niche sales channels can create a real edge.
- High unmet need supports pricing power
- Specialized trials build hard-to-copy know-how
- Niche channels can lower launch risk
- That expertise helps future deals and licensing
Zevra's CNS pipeline and brands could unlock a bigger growth story
Zevra Therapeutics, Inc. can grow through KP1077 and KP879 if Phase II data are strong, while AZSTARYS and APADAZ can add steady commercial cash flow. The upside is a broader CNS portfolio, more partnering leverage, and less dependence on rare-disease sales.
| Opportunity | Key data |
|---|---|
| KP1077 | Idiopathic hypersomnia, narcolepsy |
| KP879 | 4.2M stimulant misuse cases, 2024 |
| AZSTARYS | About 7M U.S. children with ADHD |
| APADAZ | Second revenue stream |
Threats
Clinical trial failure risk
KP1077 and KP879 are both in Phase II, so a single efficacy miss or safety issue could cut Zevra Therapeutics, Inc.'s pipeline value fast. For a small biopharma, that kind of setback can matter more than for large peers because it can hit valuation, funding access, and partner interest at the same time. With only early-to-midstage data in hand, the clinical trial failure risk stays high.
Regulatory approval uncertainty
After MIPLYFFA’s Sep. 20, 2024 FDA approval, Zevra Therapeutics, Inc. still faces full safety-and-efficacy review on every new program. Rare CNS assets and controlled-substance products often draw extra scrutiny, so timing can slip and labels can stay narrow. That leaves approval dates, use limits, and revenue timing uncertain.
Competition in ADHD and CNS markets
AZSTARYS faces a crowded U.S. ADHD market, where about 7 million children aged 3 to 17 and 15.5 million adults are diagnosed with ADHD. That scale draws many stimulants and nonstimulants, so new launches can squeeze market share, slow physician adoption, and force price pressure.
Other firms are also targeting sleep disorders and stimulant-related conditions, which raises the risk of direct competition across multiple CNS niches. For Zevra Therapeutics, Inc., even small shifts in formulary access can matter because prescribers often switch fast when rivals offer lower cost or easier dosing.
Controlled-substance and safety risk
Zevra Therapeutics, Inc. faces clear controlled-substance risk because APADAZ is a Schedule II opioid, and KP879 sits in a stimulant-sensitive area that draws tighter FDA and payer scrutiny. In the U.S., opioids were linked to about 81,000 overdose deaths in 2023, so even a small safety signal can trigger label changes, extra REMS-style controls, or slower prescribing.
That can hurt trust, limit uptake, and raise legal and compliance costs fast.
- Schedule II drugs face strict monitoring
- Safety issues can cut prescription volume
- Misuse concerns can slow payer coverage
- Any label change can damage reputation
Dependence on reimbursement and access
Zevra Therapeutics, Inc. depends on payer coverage and fast patient access to turn approvals into sales. Rare-disease and specialty CNS drugs often face prior authorization, step edits, and high copays, so even a strong label can stall uptake. In a market where specialty medicines drive most U.S. drug spend, any pricing pushback can slow prescriptions and cap revenue.
Payer controls can delay starts.
Copays can block fills.
Price pressure can cut uptake.
Zevra’s Pipeline and ADHD Market Face Major Risk
Zevra Therapeutics, Inc. still faces high pipeline risk: KP1077 and KP879 are only in Phase II, so one trial miss can erase value fast. MIPLYFFA’s Sep. 20, 2024 FDA approval helps, but every new CNS or controlled-substance asset can face slower review and narrow labels. AZSTARYS also fights a crowded ADHD market with 7 million U.S. children and 15.5 million adults diagnosed.
| Threat | Key risk |
|---|---|
| Phase II pipeline | Clinical failure risk |
| Controlled substances | FDA, payer, misuse scrutiny |
| ADHD competition | Price and share pressure |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.